About 3.4 million Americans have epilepsy. Most become seizure-free with one or two medicines, but about 1 in 3 keep having seizures despite trying several (drug-resistant epilepsy). For them, options include newer medicines such as cenobamate, surgery or laser ablation, nerve stimulation devices and the ketogenic diet. Research is bringing the first new drug classes in years, gene-targeted treatments for rare genetic epilepsies, and cell and gene therapies that could repair the seizure focus itself.
- 513studies open or running
- 36phase 3 trials
- 3,841papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
A new class for focal seizuresHappened 53.2% median seizure drop
Azetukalner, a potassium-channel opener, cut monthly focal seizures by a median 53.2% vs 10.4% with placebo in phase 3.
53.2%: median drop in monthly seizures with 25 mg, vs 10.4% with placebo.
Cenobamate makes many seizure-freeHappened 52.4% seizure-free
In a large Asian trial, 52.4% on the highest dose were seizure-free during maintenance vs 2.6% on placebo.
52.4%: seizure-free during maintenance with 400 mg, vs 2.6% with placebo.
Precision drugs for severe childhood epilepsiesHappened 59.8% drop in motor seizures (bexicaserin)
Bexicaserin cut motor seizures 59.8% vs 17.4% in DEEs; zorevunersen, which restores a missing sodium channel in Dravet syndrome, was followed by large seizure drops in open-label studies.
59.8%: median drop in motor seizures with bexicaserin, vs 17.4% with placebo.
-
6 months
by May 2027
BHV-7000 phase 3 resultsLikely
Bexicaserin for severe childhood epilepsiesLikely 59.8% drop in motor seizures
DEEp SEA (367 people) tests bexicaserin in Dravet, Lennox-Gastaut and other DEEs; due October 2026.
59.8%: median drop in motor seizures, vs 17.4% with placebo.
Azetukalner approval applicationPossible 53.2% median seizure drop
After positive phase 3 results, Xenon could submit azetukalner to regulators.
53.2%: median drop in monthly seizures with 25 mg, vs 10.4% with placebo.
-
12 months
by Nov 2027
Zorevunersen phase 3Possible 58.82% or greater seizure drop (open-label)
Stoke's EMPEROR (170 children) is the first placebo-controlled test of a disease-targeting drug for Dravet syndrome; due March 2027.
58.82%: or greater median drop in convulsive seizures at the highest dose, without a comparison group.
Azetukalner for generalized seizuresPossible
X-ACKT (160 people) tests azetukalner for primary generalized tonic-clonic seizures; due April 2027.
Vormatrigine, a sodium-channel drugPossible
Praxis's POWER2 (300 people) is due January 2027.
-
3 years
by late 2029
Cell therapy for temporal lobe epilepsyPossible
Neurona's EPIC (88 people, due February 2029) implants lab-grown calming nerve cells into the seizure focus, instead of removing brain tissue.
A drug for juvenile myoclonic epilepsyPossible
Jazz's JZP926 trial (260 people) is due August 2028.
-
5 years
by late 2031
More targeted focal-epilepsy pillsPossible
Gene therapy and preventionLong shot
Gene therapy for temporal lobe epilepsy (AMT-260) and trials to prevent epilepsy after brain injury could change care for some groups.
The research paths
Potassium-channel openers
53.2% median seizure dropDetails and 4 trialsHide
Azetukalner and BHV-7000 open Kv7 channels that quiet overexcited nerve cells, a mechanism not used by current medicines.
WatchRISE 2 and 3; X-TOLE3; X-ACKT.
- BHV-7000 for focal seizures (RISE 3)Biohaven · 390 people · fully enrolled Oct 2026
- BHV-7000 for focal seizures (RISE 2)Biohaven · 390 people · fully enrolled Dec 2026
- Azetukalner for focal seizures (X-TOLE3)Xenon · 360 people · enrolling Jan 2028
- Azetukalner for generalized tonic-clonic seizures (X-ACKT)Xenon · 160 people · enrolling Apr 2027
Precision drugs for genetic epilepsies
59.8% drop in motor seizuresDetails and 3 trialsHide
Antisense drugs and targeted pills for Dravet, Lennox-Gastaut, SCN2A and other genetic epilepsies.
WatchEMPEROR; DEEp SEA; EMERALD.
New pills for focal seizures
52.4% seizure-freeDetails and 5 trialsHide
Sodium-channel and receptor-targeted drugs aiming for higher seizure-freedom with fewer side effects.
WatchPOWER2; FOCUS 1 and 2.
- Vormatrigine for focal seizures (POWER2)Praxis Precision Medicines · 300 people · fully enrolled Jan 2027
- Vormatrigine for focal seizuresPraxis Precision Medicines · 700 people · enrolling May 2028
- RAP-219 for focal seizures (FOCUS 1)Rapport Therapeutics · 333 people · enrolling Jul 2029
- RAP-219 for focal seizures (FOCUS 2)Rapport Therapeutics · 312 people · enrolling Jul 2029
- JZP926 for juvenile myoclonic epilepsyJazz Pharmaceuticals · 260 people · enrolling Aug 2028
Cell and gene therapy
Details and 3 trialsHide
Implanted calming nerve cells and gene therapy that turn down overactive circuits in temporal lobe epilepsy.
WatchEPIC; AMT-260.
Borrowed from other conditions
From Depression research
Azetukalner
Phase 3
Also in phase 3 trials for major depression and bipolar depression.
From Serotonin drugs like fenfluramine
Bexicaserin
Phase 3
Targets the same 5-HT2C receptor thought to explain fenfluramine benefit in Dravet syndrome, without its other effects.
Open to join now
-
Focal seizures
Azetukalner
Locations and eligibility → -
Generalized tonic-clonic seizures
Azetukalner
Locations and eligibility → -
Drug-resistant temporal lobe epilepsy
NRTX-1001 cell therapy
Locations and eligibility → -
Focal seizures
RAP-219
Locations and eligibility → -
Juvenile myoclonic epilepsy
JZP926
Locations and eligibility →
See every recruiting Epilepsy trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Azetukalner cuts focal seizures in phase 3
X-TOLE2, JAMA Neurology.
Zorevunersen early results in Dravet syndrome
NEJM.
Bexicaserin reduces seizures in DEEs
PACIFIC, Epilepsia.
Standard treatment today
- New diagnosisOne seizure medicine, such as levetiracetam or lamotrigine, chosen by seizure type, age and pregnancy plans.
- Seizures continue after 2 medicinesReferral to an epilepsy center; add-on medicines such as cenobamate; testing for surgery.
- Drug-resistant focal epilepsySurgery or laser ablation when the focus can be located; VNS, responsive neurostimulation or deep brain stimulation otherwise.
- Genetic and childhood epilepsiesFenfluramine, cannabidiol, stiripentol and other syndrome-specific drugs; ketogenic diet; genetic testing.
How to read this page, and sourcesHow to read this page, and sources
- Never stop or change seizure medicine without your doctor; sudden changes can trigger severe seizures.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Epilepsy trials recruiting now →